Page last updated: 2024-12-09
aeg 3482
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AEG 3482: an antiapoptotic compound that induces expression of Hsp70; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 698112 |
| CHEMBL ID | 19231 |
| CHEBI ID | 114182 |
| SCHEMBL ID | 2540289 |
| MeSH ID | M0499837 |
Synonyms (39)
| Synonym |
|---|
| 6-phenylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide |
| HMS3269J11 |
| TIMTEC1_001442 |
| OPREA1_698164 |
| NCGC00167812-02 |
| NCGC00167812-01 |
| CHEBI:114182 |
| HMS1538B12 , |
| CHEMBL19231 |
| 63735-71-7 |
| BCP9000242 |
| aeg 3482 |
| aeg-3482 |
| unii-7ezf1a283n |
| imidazo(2,1-b)-1,3,4-thiadiazole-2-sulfonamide, 6-phenyl- |
| 6-phenylimidazo(2,1-b)-1,3,4-thiadiazole-2-sulfonamide |
| 7ezf1a283n , |
| BRD-K77634909-001-01-9 |
| CCG-221955 |
| SCHEMBL2540289 |
| 6-phenyl-imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonic acid amide |
| 6-phenylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide |
| AKOS024457221 |
| imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide, 6-phenyl- |
| Q27195229 |
| DTXSID80213176 |
| aeg 3482, >=98% (hplc) |
| FT-0736105 |
| HMS3677N15 |
| BCP01890 |
| HMS3413N15 |
| BRD-K77634909-001-02-7 |
| NCGC00167812-06 |
| aeg3482 |
| 6-phenyl-imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide |
| MS-23975 |
| HY-107599 |
| CS-0028938 |
| E98712 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| imidazoles | A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 33.5521 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID50177 | In vitro inhibition of carbonic anhydrase was determined using enzyme prepared from mouse erythrocytes | 1980 | Journal of medicinal chemistry, Feb, Volume: 23, Issue:2 | Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides. |
| AID226919 | Anticonvulsant potency in mice relative to compound UK-12130 (ED50 of compound 24/compound) | 1980 | Journal of medicinal chemistry, Feb, Volume: 23, Issue:2 | Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides. |
| AID131557 | Protective dose against maximal electroshock in mice after peroral administration | 1980 | Journal of medicinal chemistry, Feb, Volume: 23, Issue:2 | Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides. |
| AID26085 | pKa of the compound was determined | 1980 | Journal of medicinal chemistry, Feb, Volume: 23, Issue:2 | Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.16
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.16) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||